Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is the third-largest pharmaceutical...
-
Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer
-
MariMed partners with Susan G. Komen and the Keep A Breast Foundation for third annual breast cancer awareness campaign this October.
-
OCALA, Fla., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published a...
-
AUSTIN, Texas, Sept. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market...
-
A certificate of grant for Propanc’s “proenzyme composition” patent was received from the US Patent & Trademark Office.
-
iPETcertum™ by Claritas, Automated Segmentation and Accurate Quantification in PET, PET-CT/MRI Scans, Receives Brazilian Clearance from ANVISA
-
PHOENIX, Ariz. and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk...
-
UTR Therapeutics Inc Publishes Data supporting US FDA IND for a First-in-Human Clinical Trial of mRNA destabilizing drug targeting c-MYC driven cancer
-
PHOENIX and LONDON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of...